{ "version": "2.2", "instance": { "ka-20230930.htm": { "nsprefix": "ka", "nsuri": "http://www.kinetabio.com/20230930", "dts": { "inline": { "local": [ "ka-20230930.htm" ] }, "schema": { "local": [ "ka-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "ka-20230930_cal.xml" ] }, "definitionLink": { "local": [ "ka-20230930_def.xml" ] }, "labelLink": { "local": [ "ka-20230930_lab.xml" ] }, "presentationLink": { "local": [ "ka-20230930_pre.xml" ] } }, "keyStandard": 250, "keyCustom": 70, "axisStandard": 26, "axisCustom": 0, "memberStandard": 29, "memberCustom": 44, "hidden": { "total": 11, "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 363, "entityCount": 1, "segmentCount": 76, "elementCount": 763, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 819, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R3": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R5": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedCondensedConsolidatedStatementsOfOperationsParenthetical", "longName": "100050 - Statement - Condensed Condensed Consolidated Statements of Operations (Parenthetical)", "shortName": "Condensed Condensed Consolidated Statements of Operations (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "ka:InterestExpenseRelatedParties", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "ka:InterestExpenseRelatedParties", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit", "longName": "100060 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Deficit)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_3ecbb7de-b385-45f4-8cb9-3a786a8414df", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e22d4809-4252-48c0-87f5-156e8e6917b2", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R7": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "longName": "100070 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:ChangeInFairValueOfNotesPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R8": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidity", "longName": "100080 - Disclosure - Organization and Liquidity", "shortName": "Organization and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "100110 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureBalanceSheetComponents", "longName": "100120 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayable", "longName": "100130 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "100140 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreements", "longName": "100150 - Disclosure - Strategic License Agreements", "shortName": "Strategic License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:StrategicLicenseAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:StrategicLicenseAgreementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquity", "longName": "100160 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreement", "longName": "100170 - Disclosure - Collaboration Agreement", "shortName": "Collaboration Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:CollaborationAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:CollaborationAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantsAgreement", "longName": "100180 - Disclosure - Grants Agreement", "shortName": "Grants Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreement", "longName": "100190 - Disclosure - Licensing Revenue Agreement", "shortName": "Licensing Revenue Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensation", "longName": "100200 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShare", "longName": "100220 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "longName": "100230 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEvents", "longName": "100240 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:BasisOfPresentationAndConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:BasisOfPresentationAndConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "100270 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:ScheduleOfChangesInTheFairValueOfTheRightsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:ScheduleOfChangesInTheFairValueOfTheRightsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsTables", "longName": "100280 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableTables", "longName": "100290 - Disclosure - Notes Payable (Tables)", "shortName": "Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "longName": "100300 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityTables", "longName": "100310 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementTables", "longName": "100320 - Disclosure - Collaboration Agreement (Tables)", "shortName": "Collaboration Agreement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:SummaryOfCollaborationRevenueAgreementAndDeferredRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ka:CollaborationAgreementTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:SummaryOfCollaborationRevenueAgreementAndDeferredRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ka:CollaborationAgreementTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureLicensingRevenueAgreementTables", "longName": "100330 - Disclosure - Licensing Revenue Agreement - (Tables)", "shortName": "Licensing Revenue Agreement - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "longName": "100340 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareTables", "longName": "100360 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "longName": "100370 - Disclosure - Organization and Liquidity - Additional Information (Details)", "shortName": "Organization and Liquidity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_34306469-913f-4ea6-b74e-4fa781ed5118", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_de2629f3-eb5b-4f3b-bfce-475de8b9ef71", "name": "ka:ProceedsFromPrivatePlacement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R34": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "longName": "100390 - Disclosure - Reverse Merger (Additional Information) (Details)", "shortName": "Reverse Merger (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "100420 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4a37f62f-db31-4c4d-8ddf-c198983df0c3", "name": "us-gaap:LongTermDebtTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R37": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails", "longName": "100430 - Disclosure - Fair Value Measurements - Schedule Of Changes In The Fair Value Of The Rights (Details)", "shortName": "Fair Value Measurements - Schedule Of Changes In The Fair Value Of The Rights (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_1fe2b953-15b7-46d8-862a-1158e0ea7710", "name": "us-gaap:ServicingAssetAtFairValueOtherChangesInFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_976b13db-c8ea-4de6-9208-036ca99a67fd", "name": "us-gaap:ServicingAssetAtFairValueAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ka:ScheduleOfChangesInTheFairValueOfTheRightsTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R38": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails", "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of 2022 & 2020 Notes Payable Measured Using Level 3 Inputs (Details)", "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of 2022 & 2020 Notes Payable Measured Using Level 3 Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "longName": "100450 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "100460 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_d3011fee-1e34-4592-80a3-8bc87f781c35", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3011fee-1e34-4592-80a3-8bc87f781c35", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "longName": "100470 - Disclosure - Balance Sheet Components (Additional Information) (Details)", "shortName": "Balance Sheet Components (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:ProceedsFromSaleOfForeclosedAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R42": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails", "longName": "100480 - Disclosure - Notes Payable - Schedule of Notes Payable (Details)", "shortName": "Notes Payable - Schedule of Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:NotesPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:NotesPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails", "longName": "100490 - Disclosure - Notes Payable - Schedule of Expected Future Minimum Principal (Details)", "shortName": "Notes Payable - Schedule of Expected Future Minimum Principal (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "longName": "100500 - Disclosure - Notes Payable - Additional Information (Details)", "shortName": "Notes Payable - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9853aa07-475a-4095-a712-1d9924ba6b13", "name": "us-gaap:ConvertibleDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R45": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "100510 - Disclosure - Commitments and Contingencies (Additional Information) (Details)", "shortName": "Commitments and Contingencies (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_3d6568af-97b6-479d-a223-47f5506b8b6d", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3d6568af-97b6-479d-a223-47f5506b8b6d", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails", "longName": "100520 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Future Undiscounted Payments (Details)", "shortName": "Commitments and Contingencies - Schedule of Operating Lease Future Undiscounted Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesSupplementalInformationDetails", "longName": "100530 - Disclosure - Commitments and Contingencies - Schedule of Operating Leases Supplemental Information (Details)", "shortName": "Commitments and Contingencies - Schedule of Operating Leases Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ka:ScheduleOfOperatingLeasesSupplementalInformation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ka:ScheduleOfOperatingLeasesSupplementalInformation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails", "longName": "100540 - Disclosure - Commitments and Contingencies - Schedule of Finance Lease Future Undiscounted Payments (Details)", "shortName": "Commitments and Contingencies - Schedule of Finance Lease Future Undiscounted Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeasesSupplementalInformationDetails", "longName": "100550 - Disclosure - Commitments and Contingencies - Schedule of Finance Leases Supplemental Information (Details)", "shortName": "Commitments and Contingencies - Schedule of Finance Leases Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "ka:ScheduleOfFinanceLeasesSupplementalInformationTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "ka:ScheduleOfFinanceLeasesSupplementalInformationTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails", "longName": "100560 - Disclosure - Strategic License Agreements - Additional Information (Details)", "shortName": "Strategic License Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:CommonStockValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:MilestonesAchieved", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ka:StrategicLicenseAgreementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R51": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails", "longName": "100570 - Disclosure - Shareholders' Equity - Schedule of Warrants to Purchase (Details)", "shortName": "Shareholders' Equity - Schedule of Warrants to Purchase (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "longName": "100580 - Disclosure - Shareholders' Equity - Additional Information (Details)", "shortName": "Shareholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ProceedsFromWarrantExercises", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_34306469-913f-4ea6-b74e-4fa781ed5118", "name": "ka:OutstandingPrincipalAndAccruedInterestUnderTheOtherNotesPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R53": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails", "longName": "100590 - Disclosure - Shareholder's Equity - Schedule of Common Stock for Future Issuance (Details)", "shortName": "Shareholder's Equity - Schedule of Common Stock for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfCollaborationRevenueAgreementAndDeferredRevenueDetails", "longName": "100600 - Disclosure - Collaboration Agreement - Summary of collaboration revenue agreement and deferred revenue (Details)", "shortName": "Collaboration Agreement - Summary of collaboration revenue agreement and deferred revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:DeferredRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ka:SummaryOfCollaborationRevenueAgreementAndDeferredRevenueTableTextBlock", "div", "ka:CollaborationAgreementTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "ka:DecreaseForProvisionOfResearchsServices", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ka:SummaryOfCollaborationRevenueAgreementAndDeferredRevenueTableTextBlock", "div", "ka:CollaborationAgreementTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R55": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails", "longName": "100610 - Disclosure - Collaboration Agreement (Additional Information) (Details)", "shortName": "Collaboration Agreement (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_34607ff7-ee47-424a-a165-d0d4201c8451", "name": "us-gaap:DeferredRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ka:SummaryOfCollaborationRevenueAgreementAndDeferredRevenueTableTextBlock", "div", "ka:CollaborationAgreementTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_13561eaf-221d-42fa-bdd2-5062765d41d1", "name": "us-gaap:DeferredRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ka:CollaborationAgreementTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R56": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails", "longName": "100620 - Disclosure - Grant Agreement - Additional Information (Details)", "shortName": "Grant Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "ka:RecognizedGrantRevenueFromFederalAgencies", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "ka:RecognizedGrantRevenueFromFederalAgencies", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementSummaryOfLicensingRevenueAgreementsDetails", "longName": "100630 - Disclosure - Licensing Revenue Agreement - Summary Of Licensing Revenue Agreements (Details)", "shortName": "Licensing Revenue Agreement - Summary Of Licensing Revenue Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "ka:LicensingRevenueAgreementBeginningBalance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "ka:LicensingRevenueAgreementBeginningBalance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "longName": "100640 - Disclosure - Licensing Revenue Agreement - Additional Information (Details)", "shortName": "Licensing Revenue Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_fbe72f49-6c6d-4665-a7f2-514fd5393d2d", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R59": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "longName": "100650 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R60": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails", "longName": "100660 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0309e8e2-ce1f-482e-bb1b-cc2a467702bc", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R61": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails", "longName": "100670 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Stock Options Granted for Employee and Non-Employee Awards (Details)", "shortName": "Stock-Based Compensation - Summary of Fair Value of Stock Options Granted for Employee and Non-Employee Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_075c4013-dd76-45f6-90e1-b984040b908c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_075c4013-dd76-45f6-90e1-b984040b908c", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R62": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompaniesRestrictedStockActivityDetail", "longName": "100680 - Disclosure - Stock-Based Compensation - Summary of Companies Restricted Stock Activity (Detail)", "shortName": "Stock-Based Compensation - Summary of Companies Restricted Stock Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b4d4ee93-e80e-4543-9ddf-74e842c73987", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail", "longName": "100690 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation (Detail)", "shortName": "Stock-Based Compensation - Summary of Total Stock-Based Compensation (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b355c242-80ac-4900-aa60-da1dfae7c2e8", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R64": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail", "longName": "100750 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss per Share (Detail)", "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "longName": "100760 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss per Share (Parenthetical) (Details)", "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss per Share (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_d65a42ed-a83c-4eb7-a935-16d71d11edac", "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "p", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d65a42ed-a83c-4eb7-a935-16d71d11edac", "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "p", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail", "longName": "100770 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding (Detail)", "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "longName": "100780 - Disclosure - Net Loss Per Share (Additional Information) (Details)", "shortName": "Net Loss Per Share (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "longName": "100790 - Disclosure - Related Party Transactions - Additional Information (Details)", "shortName": "Related Party Transactions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_41e2f68c-20e1-4abc-bda5-39c784c0d017", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7d2d3291-04cf-45fd-bd21-1333d2e37250", "name": "ka:IssuanceOfWarrantsToExistingStockholdersShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } }, "R69": { "role": "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "100800 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_34306469-913f-4ea6-b74e-4fa781ed5118", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_87040647-70b8-4609-89cd-df07db66df38", "name": "ka:Totalofferingrelaatedfee", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ka-20230930.htm", "unique": true } } }, "tag": { "ka_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFundingProbability": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFundingProbability", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Funding Probability", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Funding Probability", "terseLabel": "Funding probability" } } }, "auth_ref": [] }, "ka_RsuVest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RsuVest", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "RSU vest", "label": "RSU vest" } } }, "auth_ref": [] }, "ka_CommonStockWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CommonStockWarrantsIssued", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock warrants issued", "label": "Common Stock Warrants Issued", "documentation": "Common stock warrants issued." } } }, "auth_ref": [] }, "ka_AccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "AccruedCompensation", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued Compensation", "label": "Accrued Compensation" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r115", "r142", "r628", "r663", "r668", "r677", "r713", "r825" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash payment of creditors", "label": "Repayments of Debt", "verboseLabel": "Convertible notes", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r866" ] }, "ka_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "EquityIncentivePlanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan [Member]", "label": "Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "ka_IssuanceOfCommonStockValueUponExtinguishmentOfNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfCommonStockValueUponExtinguishmentOfNotePayable", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance Of Common Stock Value Upon Extinguishment Of Note Payable", "documentation": "Issuance of common stock value upon extinguishment of notes payable.", "terseLabel": "Issuance of common stock upon extinguishment of notes payable and accrued interest" } } }, "auth_ref": [] }, "ka_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Increase decrease in operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r98", "r156" ] }, "ka_FairValueConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value convertible debt", "label": "Fair value convertible debt" } } }, "auth_ref": [] }, "ka_TwoThousandTwentyTwoEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2022 Equity Incentive Plan", "documentation": "Two Thousand Twenty Two Equity Incentive Plan [Member]", "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]", "terseLabel": "2022 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "ka_TwoThousandAndTwentyEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandAndTwentyEquityIncentivePlanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Twenty Equity Incentive Plan [Member]", "label": "Two Thousand And Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "ka_BoardMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "BoardMemberMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board Member", "label": "Board Member [Member]", "documentation": "Board Member [Member]" } } }, "auth_ref": [] }, "ka_SalesMilestonesMaximumAmountExpectedToPay": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SalesMilestonesMaximumAmountExpectedToPay", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales milestone, aggregate amount payable", "label": "Sales Milestones Maximum Amount Expected To Pay", "documentation": "Sales milestones, maximum amount expected to pay." } } }, "auth_ref": [] }, "ka_StockOptionsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "StockOptionsAndRestrictedStockUnitsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options And Restricted Stock Units", "label": "Stock Options And Restricted Stock Units [Member]", "documentation": "Stock options and restricted stock units." } } }, "auth_ref": [] }, "ka_RaymondBartoszekMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RaymondBartoszekMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raymond Bartoszek", "label": "Raymond Bartoszek [Member]", "documentation": "Raymond Bartoszek [Member]" } } }, "auth_ref": [] }, "ka_BasisOfPresentationAndConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "BasisOfPresentationAndConsolidationPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Consolidation", "label": "Basis Of Presentation And Consolidation Policy [Text Block]", "documentation": "Basis of presentation and consolidation." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Incremental borrowing rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r573", "r824" ] }, "ka_PaymentOfUpfrontOptionExerciseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PaymentOfUpfrontOptionExerciseFee", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront option exercise fee", "label": "Payment Of Upfront Option Exercise Fee", "documentation": "Payment of upfront option exercise fee." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnSalesOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnSalesOfAssets", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Gain (Loss) on Disposition of Assets for Financial Service Operations, Total", "label": "Gain (Loss) on Disposition of Assets for Financial Service Operations", "negatedLabel": "Gain on disposal of asset", "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations." } } }, "auth_ref": [] }, "ka_NationalInstitutesOfHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NationalInstitutesOfHealthMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "National Institutes Of Health", "label": "National Institutes Of Health [Member]", "documentation": "National Institutes of Health." } } }, "auth_ref": [] }, "ka_ReverseMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ReverseMergerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Reverse Merger [Member]", "label": "Reverse Merger [Member]" } } }, "auth_ref": [] }, "ka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsInprocessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsInprocessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Inprocess Research and Development", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Inprocess Research and Development", "terseLabel": "In-process research and development" } } }, "auth_ref": [] }, "ka_FairValueMeasurementsMinimumPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueMeasurementsMinimumPurchasePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair Value Measurements Minimum Purchase Price", "label": "Fair Value Measurements Minimum Purchase Price", "terseLabel": "Minimum purchase price" } } }, "auth_ref": [] }, "ka_OutstandingPrincipalAndAccruedInterestUnderTheOtherNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OutstandingPrincipalAndAccruedInterestUnderTheOtherNotesPayable", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "outstanding principal and accrued interest under the other notes payable", "label": "outstanding principal and accrued interest under the other notes payable", "terseLabel": "Outstanding principal and accrued interest under the other notes payable" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r360", "r406", "r407", "r408", "r409", "r410", "r411", "r536", "r591", "r592", "r593", "r807", "r808", "r813", "r814", "r815" ] }, "ka_NotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NotesPayableMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable [Member]", "documentation": "Notes payable.", "terseLabel": "2020 Notes Payable" } } }, "auth_ref": [] }, "ka_FairValueOfWarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueOfWarrantsIssued", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants issued", "label": "Fair Value Of Warrants Issued", "documentation": "Fair Value Of Warrants Issued." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Incremental borrowing rate", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r573", "r824" ] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Lease term", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r935" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Future Undiscounted Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r934" ] }, "ka_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpiredStartDate": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpiredStartDate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Class Of Warrant Or Right Date From Which Warrants Or Rights Expired Start Date", "documentation": "Class of warrant or right date from which warrants or rights expired start date." } } }, "auth_ref": [] }, "ka_DecreaseForProvisionOfResearchServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DecreaseForProvisionOfResearchServices", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementSummaryOfLicensingRevenueAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease for provision of research services", "label": "Decrease For Provision Of Research Services", "documentation": "Decrease For Provision Of Research Services." } } }, "auth_ref": [] }, "ka_IncreaseDueToAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IncreaseDueToAcquisition", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementSummaryOfLicensingRevenueAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase due to acquisition", "label": "Increase due to acquisition" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Future Minimum Principal", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r7" ] }, "ka_OrganizationAndLiquidityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OrganizationAndLiquidityTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization And Liquidity [Table]", "label": "Organization And Liquidity [Table]", "documentation": "Organization and liquidity." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r574" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r572", "r824" ] }, "ka_IncomeTaxDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IncomeTaxDisclosureLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Income Tax Disclosure [Line Items]", "label": "Income Tax Disclosure [Line Items]" } } }, "auth_ref": [] }, "ka_TheWellcomeTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TheWellcomeTrustMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Wellcome Trust", "label": "The Wellcome Trust [Member]", "documentation": "The Wellcome Trust." } } }, "auth_ref": [] }, "ka_TwoThousandTwentyConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyConvertibleNotesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Convertible Notes", "label": "Two Thousand Twenty Convertible Notes [Member]", "documentation": "Two thousand twenty convertible notes." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets, Fair Value Disclosure, Total", "label": "Assets, Fair Value Disclosure", "terseLabel": "Fair value measurement", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r96" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "ka_ChangeInFairValueOfRightsFromPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ChangeInFairValueOfRightsFromPrivatePlacement", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Change in Fair Value of Rights from Private Placement", "label": "Change in Fair Value of Rights from Private Placement", "terseLabel": "Change in fair value of rights from Private Placement", "negatedLabel": "Change in fair value of rights from Private Placement" } } }, "auth_ref": [] }, "ka_MarionRFooteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MarionRFooteMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marion R. Foote", "label": "Marion R. Foote [Member]", "documentation": "Marion R. Foote [Member]" } } }, "auth_ref": [] }, "ka_InterestExpenseRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "InterestExpenseRelatedParties", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedCondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Interest Expense Related Parties", "label": "Interest Expense Related Parties" } } }, "auth_ref": [] }, "ka_TwoZeroTwoZeroNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoZeroTwoZeroNotesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Notes", "label": "Two Zero Two Zero Notes [Member]", "documentation": "Two zero two zero notes." } } }, "auth_ref": [] }, "ka_WarrantOrRightsCancelledOrExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantOrRightsCancelledOrExpired", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled/Expired", "label": "Warrant Or Rights Cancelled Or Expired", "documentation": "Warrant or rights cancelled or expired." } } }, "auth_ref": [] }, "ka_KimberleeDrapkinAndScottDyllaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "KimberleeDrapkinAndScottDyllaMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Kimberlee Drapkin and Scott Dylla [Member]", "label": "Kimberlee Drapkin and Scott Dylla [Member]", "terseLabel": "Kimberlee Drapkin And Scott Dylla" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 24.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r4" ] }, "ka_IncentiveStockOptionsGrantedDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IncentiveStockOptionsGrantedDescription", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive stock options granted, description", "documentation": "Incentive stock options granted, description", "label": "Incentive stock options granted, description" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Net Deferred Tax Assets (liabilities)", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r147" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r124" ] }, "ka_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DirectorsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Directors", "label": "Directors [Member]", "documentation": "Directors [Member]" } } }, "auth_ref": [] }, "ka_LicenseAndResearchCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LicenseAndResearchCollaborationAgreementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License And Research Collaboration Agreement", "label": "License And Research Collaboration Agreement [Member]", "documentation": "License And Research Collaboration Agreement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense Benefit", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r148" ] }, "us-gaap_ServicingAssetAtFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServicingAssetAtFairValueAmount", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails" ], "lang": { "en-us": { "role": { "label": "Servicing Asset at Fair Value, Amount", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "documentation": "Fair value of an asset representing net future revenue from contractually specified servicing fees, late charges, and other ancillary revenues, in excess of future costs related to servicing arrangements." } } }, "auth_ref": [ "r595", "r596", "r597", "r598" ] }, "ka_TheUniversityOfUtahResearchFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TheUniversityOfUtahResearchFoundationMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The University Of Utah Research Foundation", "label": "The University Of Utah Research Foundation [Member]", "documentation": "The University of Utah Research Foundation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r146" ] }, "ka_CollaborationAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CollaborationAgreementTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreement", "label": "Collaboration Agreement Text Block", "documentation": "Collaboration Agreement Text Block" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "ka_PercentageOfDiscountOnCommonStockSharesIssued": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PercentageOfDiscountOnCommonStockSharesIssued", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of discount on common stock", "label": "Percentage Of Discount On Common Stock Shares Issued", "documentation": "Percentage of discount on common stock shares issued." } } }, "auth_ref": [] }, "ka_OtherNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OtherNotesPayableMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Notes Payable", "label": "Other Notes Payable [Member]", "documentation": "Other notes payable." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r5", "r149", "r179", "r491", "r492", "r871" ] }, "ka_OutstandingOwnershipPercentageOnCommonStock": { "xbrltype": "pureItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OutstandingOwnershipPercentageOnCommonStock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage on common stock", "label": "Outstanding Ownership Percentage On Common Stock", "documentation": "Outstanding ownership percentage on common stock." } } }, "auth_ref": [] }, "ka_IssuanceOfWarrantsInConnectionWithNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfWarrantsInConnectionWithNotesPayable", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of Warrants in Connection with Notes Payable", "documentation": "Issuance of Warrants in Connection with Notes Payable" } } }, "auth_ref": [] }, "ka_TwoThousandAndTenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandAndTenEquityIncentivePlanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Ten Equity Incentive Plan [Member]", "label": "Two Thousand And Ten Equity Incentive Plan [Member]", "terseLabel": "2010 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r9", "r70", "r71", "r72", "r73" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r454", "r455", "r456", "r684", "r872", "r873", "r874", "r930", "r959" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ka_IssuanceOfWarrantsForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfWarrantsForServices", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Issuance of warrants for services.", "label": "Issuance Of Warrants For Services", "terseLabel": "Issuance of warrants for services" } } }, "auth_ref": [] }, "ka_IssuanceOfCommonStockUponExtinguishmentOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfCommonStockUponExtinguishmentOfNotesPayable", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon extinguishment of notes payable and accrued interest", "label": "Issuance Of Common Stock Upon Extinguishment Of Notes Payable", "documentation": "Issuance of common stock upon extinguishment of notes payable." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument revised interest rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ka_GainLossOnFairValueMeasurementNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "GainLossOnFairValueMeasurementNotesPayable", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value measurement of notes payable", "label": "Gain Loss On Fair Value Measurement Notes Payable", "documentation": "Change in fair value measurement of notes payable." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTerm", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, term", "label": "Long-Term Debt, Term", "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r932" ] }, "ka_TwoThousandThirteenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandThirteenWarrantsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2013", "label": "Two Thousand Thirteen Warrants [Member]", "documentation": "2013 warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r13", "r112", "r113", "r142", "r684", "r757", "r783", "r840" ] }, "ka_AccruedClinicalTrialAndPreclinicalCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "AccruedClinicalTrialAndPreclinicalCosts", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued clinical trial and preclinical costs", "label": "Accrued Clinical Trial And Preclinical Costs", "documentation": "Accrued clinical trial and preclinical costs." } } }, "auth_ref": [] }, "ka_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Laboratory Equipment [Member]", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating lease agreement (in thousands)", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r566", "r571" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation State Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "ka_IncreasesForPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IncreasesForPaymentsReceived", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementSummaryOfLicensingRevenueAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increases for payments received", "label": "Increases for payments received" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r13", "r112", "r113", "r142" ] }, "us-gaap_LongTermDebtMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMeasurementInput", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, measurement input", "label": "Long-Term Debt, Measurement Input", "documentation": "Value of input used to measure long-term debt." } } }, "auth_ref": [ "r538" ] }, "ka_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreement", "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "ka_TwoThousandTwentyTwoWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyTwoWarrantsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022", "label": "Two Thousand Twenty Two Warrants [Member]", "documentation": "2022 warrants." } } }, "auth_ref": [] }, "ka_CommonStockUponConversionOfResticatedTockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CommonStockUponConversionOfResticatedTockUnits", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock upon conversion of resticated tock units", "label": "Common stock upon conversion of resticated tock units", "terseLabel": "Common stock upon conversion of restricated stock units" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Royalties Received", "terseLabel": "Milestones and royalties on net sales", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": [ "r43" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "terseLabel": "Cash payment", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r565", "r571" ] }, "ka_NonAccountableExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NonAccountableExpense", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-accountable expense", "label": "Non-accountable Expense", "documentation": "Non-accountable expense" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued, shares", "terseLabel": "Issuance of common stock, Shares", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r13", "r112", "r113", "r142", "r673", "r757", "r783" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "ka_SigaTechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SigaTechnologiesIncMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Siga Technologies Inc", "label": "Siga Technologies Inc [Member]", "documentation": "Siga Technologies Inc." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Fair Value of 2022 & 2020 Notes Payable Measured Using Level 3 Inputs", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r15", "r98" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ka_TwoThousandTwentyOneWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyOneWarrantsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021", "label": "Two Thousand Twenty One Warrants [Member]", "documentation": "2021 warrants." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r15", "r98" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ka_Totalofferingrelaatedfee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "Totalofferingrelaatedfee", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total offering-related fees", "label": "Totalofferingrelaatedfee", "documentation": "Total offering relaated fees" } } }, "auth_ref": [] }, "ka_CommonStockPurchasedForProfessionalServices": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CommonStockPurchasedForProfessionalServices", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock purchased for professional services", "label": "Common Stock Purchased For Professional Services", "documentation": "Common stock purchased for professional services." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r35", "r190", "r209", "r210", "r211", "r229", "r230", "r231", "r234", "r242", "r244", "r260", "r308", "r315", "r393", "r454", "r455", "r456", "r486", "r487", "r514", "r516", "r517", "r518", "r519", "r521", "r531", "r548", "r549", "r550", "r551", "r552", "r553", "r580", "r659", "r660", "r661", "r684", "r757" ] }, "ka_ScheduleOfChangesInTheFairValueOfTheRightsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ScheduleOfChangesInTheFairValueOfTheRightsTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule Of Changes In The Fair Value Of The Rights [Table Text Block]", "label": "Schedule Of Changes In The Fair Value Of The Rights [Table Text Block]", "terseLabel": "Changes In The Fair Value Of The Rights From Private Placement" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r858" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of restricted stock, Shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r13", "r142" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants to Purchase", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r74" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r190", "r229", "r230", "r231", "r234", "r242", "r244", "r308", "r315", "r454", "r455", "r456", "r486", "r487", "r514", "r517", "r518", "r521", "r531", "r659", "r661", "r684", "r959" ] }, "ka_DeferredTaxAssetsLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DeferredTaxAssetsLeasingArrangements", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets Leasing Arrangements", "label": "Deferred Tax Assets Leasing Arrangements", "terseLabel": "Operating lease liability" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r74" ] }, "ka_LicensingRevenueAgreementBeginningBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LicensingRevenueAgreementBeginningBalance", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementSummaryOfLicensingRevenueAgreementsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance as of December 31, 2022", "label": "Licensing Revenue Agreement Beginning Balance", "documentation": "Licensing Revenue Agreement Beginning Balance." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r190", "r209", "r210", "r211", "r229", "r230", "r231", "r234", "r242", "r244", "r260", "r308", "r315", "r393", "r454", "r455", "r456", "r486", "r487", "r514", "r516", "r517", "r518", "r519", "r521", "r531", "r548", "r549", "r550", "r551", "r552", "r553", "r580", "r659", "r660", "r661", "r684", "r757" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "ka_Employees": { "xbrltype": "decimalItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "Employees", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employees", "label": "Employees" } } }, "auth_ref": [] }, "ka_TransactionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TransactionOneMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Transaction One Member", "label": "Transaction One [Member]", "terseLabel": "Transaction One" } } }, "auth_ref": [] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r846", "r848", "r849" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Executive management purchased Shares", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r13", "r112", "r113", "r142" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon vesting of RSUs, Shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r13", "r112", "r113", "r142" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Employee-related Liabilities, Current", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Outstanding Stock Options, Exercised", "negatedLabel": "Outstanding Stock Options, Exercised", "verboseLabel": "Common stock upon exercise of warrants", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r13", "r112", "r113", "r142", "r429" ] }, "ka_TransactionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TransactionTwoMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Transaction Two Member", "label": "Transaction Two [Member]", "terseLabel": "Transaction Two" } } }, "auth_ref": [] }, "ka_WarrantsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantsExercisable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercisable", "label": "Warrants Exercisable", "documentation": "Warrants exercisable" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAbstract", "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "auth_ref": [] }, "ka_PostReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PostReverseStockSplitMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Post-Reverse Stock Split [Member]", "label": "Post-Reverse Stock Split [Member]", "terseLabel": "Post-Reverse Stock Split" } } }, "auth_ref": [] }, "ka_IssuanceOfWarrantsToExistingStockholdersShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfWarrantsToExistingStockholdersShares", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Issuance of Warrants to Existing Stockholders, Shares", "label": "Issuance of Warrants to Existing Stockholders, Shares", "terseLabel": "Issuance of warrants" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "terseLabel": "Computer and Software", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "srt_PresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PresidentMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "President", "label": "President [Member]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing revenues [Member]", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r890" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r50" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r50" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r130", "r221" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r50" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "auth_ref": [ "r415", "r875" ] }, "ka_WarrantsToPurchaseCommonStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantsToPurchaseCommonStockPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Warrants to Purchase Common Stock [Policy Text Block]", "label": "Warrants to Purchase Common Stock [Policy Text Block]", "terseLabel": "Warrants to Purchase Common Stock" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r14" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r828", "r829", "r832", "r833", "r834", "r835" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r246", "r415", "r854", "r855", "r875" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r246", "r415", "r854", "r875" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized tax benefits, penalties and interest expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r473" ] }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentOfWarrantsGrantedForServices", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment of Warrants Granted for Services", "terseLabel": "Common stock issued for services", "documentation": "Adjustment for noncash service expenses paid for by granting of warrants." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r225", "r466", "r472", "r476", "r482", "r489", "r494", "r495", "r496", "r678" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEvents", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r229", "r230", "r231", "r260", "r605", "r671", "r696", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r715", "r716", "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r726", "r727", "r728", "r729", "r730", "r732", "r735", "r736", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r757", "r831" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r300", "r301", "r302" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r208", "r468", "r469", "r476", "r477", "r481", "r483", "r672" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r113" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r85", "r86", "r497", "r816", "r817" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r921" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r497", "r816", "r817" ] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r497" ] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfLand", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Area of Land", "terseLabel": "Area of land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseExpirationDate1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r502" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r844" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Components of cash and restricted cash:", "label": "Restricted Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r175", "r178", "r631" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r13" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r171", "r860", "r867" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r11" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost not yet recognized, period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r452" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "totalLabel": "Restricted Cash, Total", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r859", "r867", "r950", "r953" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r127" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash and restricted cash", "periodStartLabel": "Cash and restricted cash at beginning of year", "periodEndLabel": "Cash and restricted cash at end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r45", "r127", "r220" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r554", "r589" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Date of Acquisition Agreement", "terseLabel": "Business acquisition, date of acquisition agreement", "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Research and Development Expense", "terseLabel": "In-process research and development", "documentation": "Amount of other research and development expense." } } }, "auth_ref": [ "r919" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r554", "r589" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEvents", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r554", "r589" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEvents", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r554", "r589" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r325", "r328", "r741" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r846", "r848", "r849" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r846", "r848", "r849" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Total notes payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r160", "r359", "r374", "r807", "r808", "r952" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r328", "r741" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEvents", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r554", "r589" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r195", "r205", "r224", "r303", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r504", "r508", "r541", "r825", "r885", "r886", "r941" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update", "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r233", "r234", "r235", "r236", "r246", "r298", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r327", "r454", "r455", "r456", "r484", "r485", "r486", "r487", "r499", "r500", "r501", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r539", "r540", "r543", "r544", "r545", "r546", "r555", "r556", "r559", "r560", "r561", "r562", "r576", "r577", "r578", "r579", "r580", "r606", "r607", "r608", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r879", "r938" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEvents", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r229", "r230", "r231", "r260", "r605", "r671", "r696", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r715", "r716", "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r726", "r727", "r728", "r729", "r730", "r732", "r735", "r736", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r757", "r831" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r214", "r237", "r238", "r239", "r240", "r241", "r250", "r253", "r254", "r255", "r259", "r532", "r533", "r621", "r637", "r800" ] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements." } } }, "auth_ref": [ "r464", "r920" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r228", "r888" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r464", "r920" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r464", "r920" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r464", "r920" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentTerms", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, maturities, repayment terms", "label": "Long-Term Debt, Maturities, Repayment Terms", "documentation": "Disclosure of timing of required repayments, sinking fund requirements, and other redeemable securities at fixed or determinable prices and dates in the five years immediately following the date of the latest balance sheet presented in the financial statements, and the amount thereafter to fully repay the principal of long-term debt. These disclosures may be made either on an individual debt or security basis, by type of debt or security basis, or on a combined basis." } } }, "auth_ref": [ "r7", "r66" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "Remainder of 2023", "verboseLabel": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r228", "r364" ] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal fees", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r121" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r228", "r364" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests [Member]", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r89", "r393", "r872", "r873", "r874", "r959" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Debt Conversion, Converted Instrument, Principal and accrued interest", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r47", "r48" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address Address Line1", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r228", "r364" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r228", "r364" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r187", "r202", "r203", "r204", "r224", "r250", "r251", "r253", "r255", "r261", "r262", "r303", "r337", "r339", "r340", "r341", "r344", "r345", "r377", "r378", "r381", "r384", "r391", "r541", "r673", "r674", "r675", "r676", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r712", "r734", "r757", "r782", "r783", "r784", "r785", "r786", "r853", "r868", "r876" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r228", "r364" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Notes payable, net of current portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r201" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r58", "r198", "r632" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r89", "r90", "r92", "r190", "r191", "r210", "r229", "r230", "r231", "r234", "r242", "r308", "r315", "r393", "r454", "r455", "r456", "r486", "r487", "r514", "r516", "r517", "r518", "r519", "r521", "r531", "r548", "r549", "r553", "r580", "r660", "r661", "r682", "r714", "r731", "r758", "r759", "r787", "r840", "r870", "r880", "r933", "r959" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "terseLabel": "Total Shareholders' Equity (Deficit) Attributable to Kineta [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMerger" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Reverse Merger", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r150", "r498" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r47", "r48" ] }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueArrangementByTypeTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue Arrangement By Type [Table]", "label": "Deferred Revenue Arrangement, by Type [Table]", "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r850" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r537" ] }, "us-gaap_DeferredRevenueArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueArrangementLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue Arrangement [Line Items]", "label": "Deferred Revenue Arrangement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Equity interests issued or issuable number of shares issued", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r13", "r66", "r112", "r113", "r142" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ServicingAssetAtFairValueOtherChangesInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServicingAssetAtFairValueOtherChangesInFairValue", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Servicing Asset at Fair Value, Other Changes in Fair Value", "verboseLabel": "Change in fair value of rights from Private Placement", "terseLabel": "Change in fair value of rights from Private Placement", "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer." } } }, "auth_ref": [ "r602" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r46", "r157" ] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Transaction [Domain]", "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r798" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r851" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r825" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r798" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "ka_WarrantOrRightsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantOrRightsExercised", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised", "label": "Warrant Or Rights Exercised", "documentation": "Warrant or rights exercised." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Capital Loss Carryforwards", "terseLabel": "Capital loss carryforward", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards." } } }, "auth_ref": [ "r84", "r925" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r416", "r419", "r450", "r451", "r453", "r819" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r931" ] }, "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition, Milestone Method, Revenue Recognized", "terseLabel": "Revenue recognition milestone method revenue recognized", "documentation": "The amount of consideration recognized during the period for the milestone or milestones." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r843" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r479" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r10" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total accured expense and other current liabilities", "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "totalLabel": "Total stockholders equity attributable to Kineta, Inc.", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r113", "r116", "r117", "r131", "r714", "r731", "r758", "r759", "r825", "r841", "r870", "r880", "r933", "r959" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, in Process Research and Development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r84", "r925" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r572", "r824" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r843" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense (with related parties $0 for the three and nine months ended September 30, 2023 and $465 and $1,366 for the three and nine months ended September 30, 2022, respectively)", "label": "Interest Expense", "totalLabel": "Interest Expense, Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r101", "r164", "r212", "r268", "r557", "r742", "r839", "r958" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r924" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r292", "r605", "r650", "r651", "r652", "r653", "r654", "r655", "r795", "r812", "r826", "r857", "r883", "r884", "r889", "r954" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r843" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r405", "r414", "r445", "r446", "r447", "r594", "r604", "r656", "r702", "r703", "r766", "r768", "r770", "r771", "r776", "r791", "r792", "r804", "r811", "r818", "r827", "r830", "r881", "r887", "r944", "r945", "r946", "r947", "r948" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r8", "r19" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r292", "r605", "r650", "r651", "r652", "r653", "r654", "r655", "r795", "r812", "r826", "r857", "r883", "r884", "r889", "r954" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]", "terseLabel": "Summary of Purchase Price Paid in Merger", "documentation": "Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period." } } }, "auth_ref": [ "r152" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r414", "r604", "r656", "r702", "r703", "r766", "r768", "r770", "r771", "r776", "r791", "r792", "r804", "r811", "r818", "r827", "r887", "r943", "r944", "r945", "r946", "r947", "r948" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r405", "r414", "r445", "r446", "r447", "r594", "r604", "r656", "r702", "r703", "r766", "r768", "r770", "r771", "r776", "r791", "r792", "r804", "r811", "r818", "r827", "r830", "r881", "r887", "r944", "r945", "r946", "r947", "r948" ] }, "us-gaap_DebtInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r414", "r604", "r656", "r702", "r703", "r766", "r768", "r770", "r771", "r776", "r791", "r792", "r804", "r811", "r818", "r827", "r887", "r943", "r944", "r945", "r946", "r947", "r948" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r228", "r347", "r348", "r349", "r350", "r351", "r353", "r358", "r359", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r371", "r558", "r806", "r807", "r808", "r809", "r810", "r869" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r110", "r111", "r159", "r160", "r228", "r347", "r348", "r349", "r350", "r351", "r353", "r358", "r359", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r558", "r806", "r807", "r808", "r809", "r810", "r869" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r214", "r237", "r238", "r239", "r240", "r241", "r248", "r250", "r253", "r254", "r255", "r259", "r532", "r533", "r621", "r637", "r800" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r32", "r66", "r69", "r99", "r100", "r102", "r106", "r139", "r141", "r228", "r347", "r348", "r349", "r350", "r351", "r353", "r358", "r359", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r371", "r558", "r806", "r807", "r808", "r809", "r810", "r869" ] }, "ka_TwoThousandSeventeenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandSeventeenWarrantsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017", "label": "Two Thousand Seventeen Warrants [Member]", "documentation": "2017 warrants." } } }, "auth_ref": [] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable", "label": "Notes Payable, Fair Value Disclosure", "verboseLabel": "Fair Value", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Amount of increase (decrease) in the valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r478" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r567" ] }, "ka_MerckSharpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MerckSharpMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Merck Sharp [Member]", "label": "Merck Sharp [Member]", "terseLabel": "Merck Sharp" } } }, "auth_ref": [] }, "ka_NonVotingCommonStockPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NonVotingCommonStockPercentage", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-voting common stock percentage", "label": "Non Voting Common Stock Percentage", "documentation": "Non-voting common stock percentage." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r144" ] }, "ka_ProceedsFromPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ProceedsFromPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from Private Placement", "label": "Proceeds From Private Placement", "documentation": "Proceeds From Private Placement" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r584", "r585", "r939" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable as of June 30, 2023", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r812" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r444" ] }, "ka_FutureRight": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FutureRight", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Future right recorded as other asset", "label": "Future right", "terseLabel": "Future Right Recorded as Other Asset" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment, net", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r87", "r88" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r226", "r227", "r350", "r379", "r586", "r797", "r798" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Total purchase price", "totalLabel": "Total purchase price", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r87", "r88" ] }, "us-gaap_DebtConversionDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionDescription", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Description", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestorMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investor [Member]", "terseLabel": "Investors", "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value." } } }, "auth_ref": [ "r936", "r937" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r41" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward, amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r83" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r166", "r167", "r168", "r295", "r296", "r297" ] }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardLimitationsOnUse", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Limitations on Use", "terseLabel": "Tax carryforward, limitations on use", "documentation": "Description of the limitation related to use of the tax credit carryforward." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r828", "r829", "r830", "r832", "r833", "r834", "r835", "r872", "r873", "r930", "r955", "r959" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "totalLabel": "Additional Paid in Capital, Total", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r114", "r825", "r957" ] }, "ka_MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MergerAgreementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Merger Agreement", "label": "Merger Agreement [Member]", "documentation": "Merger agreement." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r88" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address City Or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r502" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r18" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayable" ], "lang": { "en-us": { "role": { "terseLabel": "Note Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r136", "r222", "r346", "r352", "r353", "r354", "r355", "r356", "r357", "r362", "r369", "r370", "r372" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address State Or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ka_NumberOfInvestors": { "xbrltype": "integerItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NumberOfInvestors", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Investors", "label": "Number Of Investors", "documentation": "Number of investors." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateIncreaseDecrease", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, increase (decrease)", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument." } } }, "auth_ref": [] }, "ka_NonrecoursePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NonrecoursePromissoryNoteMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrecourse Promissory Note", "label": "Nonrecourse Promissory Note [Member]", "documentation": "Nonrecourse promissory note" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sublease Income", "terseLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r570", "r824" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r123" ] }, "ka_DohmeLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DohmeLlcMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Dohme LLC [Member]", "label": "Dohme LLC [Member]", "terseLabel": "Dohme LLC" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesContingentlyIssuable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares, Contingently Issuable", "label": "Weighted Average Number of Shares, Contingently Issuable", "documentation": "Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period." } } }, "auth_ref": [ "r49" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r249", "r255" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r15" ] }, "ka_AccountsReceivablePaymentReceivablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "AccountsReceivablePaymentReceivablePeriod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Payment Receivable Period", "label": "Accounts Receivable, Payment Receivable Period", "terseLabel": "Accounts receivable, payment receivable period" } } }, "auth_ref": [] }, "ka_RisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RisksAndUncertaintiesPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties", "label": "Risks And Uncertainties Policy [Text Block]", "documentation": "Risks and uncertainties." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r269" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodStartLabel": "Beginning balance of unrecognized tax benefits", "periodEndLabel": "Ending balance of unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r467", "r474" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r248", "r255" ] }, "ka_OtherExpenseIncomePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OtherExpenseIncomePolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Other (Expense) Income [Policy Text Block]", "label": "Other (Expense) Income [Policy Text Block]", "terseLabel": "Other (Expense) Income" } } }, "auth_ref": [] }, "ka_RevenueRecognitionMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RevenueRecognitionMilestonePayments", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition Milestone Payments", "label": "Revenue Recognition Milestone Payments", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "ka_NoncashOperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NoncashOperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Noncash Operating Lease Expense", "documentation": "Noncash operating lease expense." } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantsAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Grant Agreements", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": [ "r165", "r464" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r360", "r406", "r407", "r408", "r409", "r410", "r411", "r591", "r592", "r593", "r807", "r808", "r813", "r814", "r815" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r20", "r160", "r373" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfOtherAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfOtherAssets1", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds From Sale Of Other Assets 1", "label": "Proceeds from Sale of Other Assets", "documentation": "Amount of cash inflow from the sale of other assets as part of operating activities." } } }, "auth_ref": [ "r44" ] }, "ka_OptionsGrantedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OptionsGrantedPercentage", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted, percentage", "documentation": "Options granted, percentage", "label": "Options granted, percentage" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r193", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r329", "r330", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r805", "r857", "r954" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Finance Lease [Abstract]" } } }, "auth_ref": [] }, "ka_LicenseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LicenseReceivable", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "License Receivable", "label": "License Receivable", "terseLabel": "License receivable" } } }, "auth_ref": [] }, "ka_TwoThousandTwentyThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyThreeWarrantsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Three Warrants [Member]", "label": "Two Thousand Twenty Three Warrants [Member]", "terseLabel": "2023" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eligible to reveive grant funds", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r465" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross", "terseLabel": "Grant Received for Research And Development", "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r465" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease, cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r569", "r824" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized direct transaction costs", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r821", "r927", "r928", "r929" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r735", "r794", "r799" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Unrecognized Tax Benefits, Period Increase (Decrease), Total", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Increases or decreases in unrecognized tax benefits", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r923" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r462" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price Per Share, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r428" ] }, "ka_ChangeInFairValueOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ChangeInFairValueOfNotesPayable", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of notes payable", "label": "Change In Fair Value Of Notes Payable", "documentation": "Change in fair value of notes payable." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Gross increases based on tax positions related to current year", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r475" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureLicensingRevenueAgreementTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Licensing Revenue Agreements And Deferred Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r889" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price Per Share, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price Per Share, Expired", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r431" ] }, "ka_YumanityWarrantHolderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "YumanityWarrantHolderMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Yumanity Warrant Holder [Member]", "label": "Yumanity Warrant Holder [Member]", "terseLabel": "Yumanity" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueRevenueRecognized1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueRevenueRecognized1", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred Revenue", "terseLabel": "Transaction price recognized", "label": "Deferred Revenue, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Repaid, Principal", "terseLabel": "Convertible notes principal balance outstanding", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": [ "r676" ] }, "us-gaap_LessorOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseOptionToExtend", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Option to Extend", "terseLabel": "Lease term extend, description", "documentation": "Description of terms and conditions of option to extend lessor's operating lease." } } }, "auth_ref": [ "r575" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price Per Share, Forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r430" ] }, "ka_PriorMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PriorMergerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Prior merger member", "label": "Prior Merger [Member]" } } }, "auth_ref": [] }, "ka_IssuanceOfCommonStockValueUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfCommonStockValueUponExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of warrants", "label": "Issuance Of Common Stock Value Upon Exercise Of Warrants", "documentation": "Issuance of common stock Value upon exercise of warrants." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r843" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r300" ] }, "ka_IssuanceOfCommonStockSharesUponExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfCommonStockSharesUponExerciseOfWarrants", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of warrants, Shares", "label": "Issuance Of Common Stock Shares Upon Exercise Of Warrants", "documentation": "Issuance of common stock shares upon exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r132", "r197", "r633" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security12b Title", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r842" ] }, "ka_LicenseAgreementsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LicenseAgreementsDisclosureLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements Disclosure [Line Items]", "label": "License Agreements Disclosure [Line Items]", "documentation": "License agreements disclosure." } } }, "auth_ref": [] }, "ka_AdjustmentsToAdditionalPaidInCapitalNoteConversionDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "AdjustmentsToAdditionalPaidInCapitalNoteConversionDiscount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Note Conversion Discount", "label": "Adjustments to Additional Paid in Capital, Note Conversion Discount", "terseLabel": "Note conversion discount" } } }, "auth_ref": [] }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity Type of Counterparty [Domain]", "documentation": "Nature of the other party participating in a financial transaction." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for services", "label": "Stock Issued During Period, Value, Issued for Services", "verboseLabel": "Common stock issued for services", "negatedLabel": "Common stock issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "ka_ProfessionalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ProfessionalServicesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "professional services[Member]", "label": "professional services[Member]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r55", "r836", "r837", "r838", "r961" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "totalLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r623", "r633", "r825" ] }, "us-gaap_IndividualMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndividualMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Individual Counterparty [Member]", "terseLabel": "Individual Investors Member", "documentation": "Individual person that is legally permitted to enter into a contract and be sued if that person fails to meet the obligations imposed by a contract." } } }, "auth_ref": [] }, "ka_LeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LeaseAgreementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease Agreement [Member]", "label": "Lease Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable, principal", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r100", "r102", "r347", "r558", "r807", "r808" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for services, Shares", "label": "Stock Issued During Period, Shares, Issued for Services", "verboseLabel": "Number Of shares issued for service", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity of Counterparty, Type [Axis]", "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction." } } }, "auth_ref": [ "r36" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "ka_LicenseAgreementsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LicenseAgreementsDisclosureTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements Disclosure [Table]", "label": "License Agreements Disclosure [Table]", "documentation": "License agreements disclosure." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r574" ] }, "ka_WithholdingToCoverTaxesFromRsuVesting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WithholdingToCoverTaxesFromRsuVesting", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding to cover taxes from RSU vesting", "label": "Withholding To Cover Taxes From RSU Vesting", "documentation": "Withholding To Cover Taxes From RSU Vesting" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r416", "r423", "r442", "r443", "r444", "r445", "r448", "r457", "r458", "r459", "r460" ] }, "us-gaap_ServicingAssetsAtFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServicingAssetsAtFairValueLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails" ], "lang": { "en-us": { "role": { "label": "Servicing Assets at Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r598", "r599", "r600", "r601", "r603" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r88" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Companies Restricted Stock Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r79" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r88" ] }, "ka_MaturityDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MaturityDateMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity Date Member", "label": "Maturity Date [Member]", "terseLabel": "Maturity Date Member" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r281", "r293", "r803" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update", "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r233", "r234", "r235", "r236", "r246", "r298", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r327", "r454", "r455", "r456", "r484", "r485", "r486", "r487", "r499", "r500", "r501", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r539", "r540", "r543", "r544", "r545", "r546", "r555", "r556", "r559", "r560", "r561", "r562", "r576", "r577", "r578", "r579", "r580", "r606", "r607", "r608", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "ka_DavidArkowitzMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DavidArkowitzMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "David Arkowitz", "label": "David Arkowitz [Member]", "documentation": "David Arkowitz [Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairments of long-lived assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r5", "r56", "r133" ] }, "ka_IssuanceOfCommonStockSharesUponExtinguishmentOfNotesPayable": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfCommonStockSharesUponExtinguishmentOfNotesPayable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance Of Common Stock Shares Upon Extinguishment Of Notes Payable", "documentation": "Issuance of common stock shares upon extinguishment of notes payable.", "terseLabel": "Issuance of common stock upon extinguishment of notes payable and accrued interest, Shares" } } }, "auth_ref": [] }, "ka_AutomaticConversionScenarioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "AutomaticConversionScenarioMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Automatic Conversion Scenario", "label": "Automatic Conversion Scenario [Member]", "documentation": "Automatic conversion scenario." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ka_QualifiedFinancingScenarioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "QualifiedFinancingScenarioMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified Financing Scenario", "label": "Qualified Financing Scenario [Member]", "documentation": "Qualified financing scenario." } } }, "auth_ref": [] }, "ka_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTaxCreditPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTaxCreditPercent", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development Tax Credit, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development Tax Credit, Percent", "terseLabel": "Research and development tax credits" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r88" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r52", "r53", "r54", "r172", "r173", "r176", "r177" ] }, "ka_FairValueOfSharesOwnedByAcquiree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueOfSharesOwnedByAcquiree", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair Value Of Shares Owned By Acquiree", "label": "Fair Value Of Shares Owned By Acquiree", "terseLabel": "Fair value of shares of combined organization owned by Yumanity shareholders" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2023", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedTerseLabel": "Deferred revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r88" ] }, "ka_MaturityDateOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MaturityDateOneMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity Date One Member", "label": "Maturity Date One [Member]", "terseLabel": "Maturity Date One Member" } } }, "auth_ref": [] }, "ka_RegisteredOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RegisteredOfferingMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Registered Offering [Member]", "label": "Registered Offering [Member]" } } }, "auth_ref": [] }, "ka_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CollaborationRevenueMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Collaboration revenue [Member]", "documentation": "Collaboration revenue [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "ka_WarrantExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantExpense", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Warrant expense", "label": "Warrant expense", "terseLabel": "Warrant expense", "negatedLabel": "Warrant expense", "verboseLabel": "Warrant expense" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r125" ] }, "ka_WarrantOrRightsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantOrRightsIssued", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued", "label": "Warrant Or Rights Issued", "documentation": "Warrant or rights issued." } } }, "auth_ref": [] }, "ka_MilestoneExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MilestoneExpenses", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone expenses", "label": "Milestone Expenses", "documentation": "Milestone Expenses" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r574" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r78" ] }, "ka_KeithBakerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "KeithBakerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Keith Baker", "label": "Keith Baker [Member]", "documentation": "Keith Baker [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value of Stock Options Granted for Employee and Non-Employee Awards", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r145" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r132" ] }, "ka_EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustment": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "EffectiveIncomeTaxRateReconciliationDebtFairValueAdjustment", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation debt fair value adjustment", "label": "Effective Income Tax Rate Reconciliation Debt Fair Value Adjustment", "terseLabel": "Debt fair value adjustment" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Finance Lease Future Undiscounted Payments", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r934" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Number Outstanding", "periodStartLabel": "Number Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfForeclosedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfForeclosedAssets", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Foreclosed Assets", "terseLabel": "Proceeds from disposal of assets", "documentation": "The cash inflow from the sale assets received in full or partial satisfaction of a receivable including real and personal property; equity interests in corporations, partnerships, and joint ventures; and beneficial interests in trusts. Foreclosed assets also include loans that are treated as if the underlying collateral had been foreclosed because the institution has taken possession of the collateral, even though legal foreclosure or repossession proceedings have not taken place." } } }, "auth_ref": [ "r38" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ka_ExecutiveManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ExecutiveManagementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive management", "label": "Executive management [Member]", "documentation": "Executive management [Member]" } } }, "auth_ref": [] }, "ka_NonVotingCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NonVotingCommonStock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Non voting common stock", "label": "Non voting common stock" } } }, "auth_ref": [] }, "ka_CraigPhilipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CraigPhilipsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Craig Philips", "label": "Craig Philips [Member]", "documentation": "Craig Philips [Member]" } } }, "auth_ref": [] }, "ka_ShawnIadonatoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ShawnIadonatoMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shawn Iadonato", "label": "Shawn Iadonato [Member]", "documentation": "Shawn Iadonato [Member]" } } }, "auth_ref": [] }, "ka_ScheduleOfFinanceLeasesSupplementalInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ScheduleOfFinanceLeasesSupplementalInformationTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of Finance Leases Supplemental Information [Table Text Block]", "label": "Schedule of Finance Leases Supplemental Information [Table Text Block]", "terseLabel": "Schedule of Finance Leases Supplemental Information" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r535" ] }, "ka_NumberOfSharesOwnedByAcquiree": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NumberOfSharesOwnedByAcquiree", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of Shares Owned By Acquiree", "label": "Number Of Shares Owned By Acquiree", "terseLabel": "Number of shares owned by Yumanity shareholders" } } }, "auth_ref": [] }, "ka_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to Purchase Common Stock [Member]", "label": "Warrants To Purchase Common Stock [Member]", "documentation": "Warrants to purchase common stock member" } } }, "auth_ref": [] }, "ka_NonVotingCommonSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NonVotingCommonSharesIssued", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-voting common, shares, issued", "label": "Non Voting Common Shares Issued", "documentation": "Non-voting common, shares, issued." } } }, "auth_ref": [] }, "ka_ProceedsFromPayrollProtectionProgramLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ProceedsFromPayrollProtectionProgramLoan", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from Payroll Protection Program Loan", "label": "Proceeds from Payroll Protection Program Loan", "terseLabel": "Proceeds from payroll protection program loan" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity (deficit):" } } }, "auth_ref": [] }, "ka_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedweightedaveragegrantdatefairvalue": { "xbrltype": "perShareItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedweightedaveragegrantdatefairvalue", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompaniesRestrictedStockActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Released", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue", "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" } } }, "auth_ref": [] }, "ka_FinanceLeaseLiabilitiesArisingFromObtainingNewRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FinanceLeaseLiabilitiesArisingFromObtainingNewRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities arising from obtaining new right-of-use assets", "label": "Finance Lease Liabilities Arising From Obtaining New Right Of Use Assets", "documentation": "Finance lease liabilities arising from obtaining new right-of-use assets." } } }, "auth_ref": [] }, "ka_BalanceSheetComponentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "BalanceSheetComponentsLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Balance Sheet Components [Line Items]", "label": "Balance Sheet Components [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r134" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant term", "terseLabel": "Warrants to purchase shares of common stock", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r392" ] }, "ka_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r574" ] }, "ka_OperatingLossCarryforwardsExpirationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OperatingLossCarryforwardsExpirationAmount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration amount", "label": "Operating Loss Carryforwards, Expiration Amount", "terseLabel": "Operating loss carryforwards expiration amount" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Shareholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r138", "r223", "r376", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r390", "r393", "r522", "r760", "r762", "r788" ] }, "ka_RecognizedGrantRevenueFromFederalAgencies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RecognizedGrantRevenueFromFederalAgencies", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized grant revenue from federal agencies", "label": "Recognized Grant Revenue From Federal Agencies", "documentation": "Recognized grant revenue from federal agencies." } } }, "auth_ref": [] }, "ka_YumanityTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "YumanityTherapeuticsIncMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "documentation": "Yumanity Therapeutics Inc [Member]", "label": "Yumanity Therapeutics Inc [Member]", "terseLabel": "Yumanity" } } }, "auth_ref": [] }, "ka_WarrantIssuedSharesPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WarrantIssuedSharesPurchase", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant issued shares purchase", "label": "Warrant Issued Shares Purchase", "documentation": "Warrant issued shares purchase." } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r697", "r698", "r699", "r700", "r701", "r765", "r767", "r769", "r772", "r773", "r774", "r775", "r777", "r778", "r779", "r780", "r781", "r830" ] }, "ka_RemainingOwnershipPercentageOnCommonStock": { "xbrltype": "pureItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RemainingOwnershipPercentageOnCommonStock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining ownership percentage on common stock", "label": "Remaining Ownership Percentage On Common Stock", "documentation": "Remaining Ownership Percentage On Common Stock." } } }, "auth_ref": [] }, "ka_DeferredTaxLiabilitiesPartnershipBasisDeferred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DeferredTaxLiabilitiesPartnershipBasisDeferred", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, partnership basis deferred", "label": "Deferred Tax Liabilities, Partnership Basis Deferred", "terseLabel": "Partnership basis deferred" } } }, "auth_ref": [] }, "ka_FairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValue", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "fair value", "label": "fair value" } } }, "auth_ref": [] }, "ka_GeneralCounselMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "GeneralCounselMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General Counsel", "label": "General Counsel [Member]", "documentation": "General Counsel [Member]" } } }, "auth_ref": [] }, "ka_GigagenIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "GigagenIncMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gigagen, Inc", "label": "Gigagen Inc [Member]", "documentation": "Gigagen, inc." } } }, "auth_ref": [] }, "ka_PaulineKennyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PaulineKennyMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pauline Kenny", "label": "Pauline Kenny [Member]", "documentation": "Pauline Kenny [Member]" } } }, "auth_ref": [] }, "ka_LicensingRevenueAgreementEndingBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LicensingRevenueAgreementEndingBalance", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementSummaryOfLicensingRevenueAgreementsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance as of March 31, 2023", "label": "Licensing Revenue Agreement Ending Balance", "documentation": "Licensing Revenue Agreement Ending Balance." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r143" ] }, "ka_RoyaltiesDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RoyaltiesDue", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties due", "label": "Royalties Due", "documentation": "Royalties due." } } }, "auth_ref": [] }, "ka_IssuanceOfCommonStockUponCashlessExerciseOfStockOptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfCommonStockUponCashlessExerciseOfStockOptions", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon cashless exercise of stock options", "documentation": "Issuance of common stock upon cashless exercise of stock options" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability, Total", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r564" ] }, "ka_IncreaseDecreaseInLicenseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IncreaseDecreaseInLicenseReceivable", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase Decrease In License receivable", "label": "Increase Decrease In License receivable", "negatedLabel": "License receivable" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompaniesRestrictedStockActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Stock, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Restricted Stock, Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r437" ] }, "ka_GrossProceedsFromOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "GrossProceedsFromOfferings", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds from offerings", "label": "Gross Proceeds from Offerings", "documentation": "Gross proceeds from offerings" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notes Payable", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r564" ] }, "ka_SubleaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SubleaseAgreementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Sublease Agreement [Member]", "label": "Sublease Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Stock, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "SARs excercised", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r435" ] }, "ka_NonVotingCommonStockPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NonVotingCommonStockPerShare", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Voting Common Stock Per share", "label": "Non Voting Common Stock Per Share", "documentation": "Non-voting common stock per share." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Outstanding", "periodStartLabel": "Balance, Shares", "periodEndLabel": "Balance, Shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "ka_IncomeTaxBenefitValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IncomeTaxBenefitValuationAllowance", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "documentation": "Income Tax Benefit Valuation Allowance", "label": "Income Tax Benefit Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompaniesRestrictedStockActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Restricted Stock, Beginning Balance", "periodEndLabel": "Number of Restricted Stock, ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r432", "r433" ] }, "ka_MerckCoIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MerckCoIncMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Merck Co Inc [Member]", "label": "Merck Co Inc [Member]", "terseLabel": "Merck & Co., Inc." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Accrued Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "ka_StrategicLicenseAgreementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "StrategicLicenseAgreementsDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic License Agreements", "label": "Strategic License Agreements Disclosure [Text Block]", "documentation": "Strategic license agreements disclosure." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, current portion", "label": "Operating Lease, Liability, Current", "verboseLabel": "Less: Operating lease liability, current portion", "negatedTerseLabel": "Less: Operating lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r564" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompaniesRestrictedStockActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, Beginning Balance", "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, Ending Balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of cost not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r452" ] }, "ka_OtherEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OtherEmployeesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Employees [Member]", "label": "Other Employees [Member]", "documentation": "Other Employees [Member]" } } }, "auth_ref": [] }, "ka_DebtInstrumentDefaultInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DebtInstrumentDefaultInterestRate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument default interest rate", "label": "Debt instrument default interest rate", "terseLabel": "Debt instrument default interest rate" } } }, "auth_ref": [] }, "ka_AggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "AggregatePurchasePrice", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "aggregate purchase price", "label": "aggregate purchase price" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r94", "r95" ] }, "ka_PaymentsForOptionAndLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PaymentsForOptionAndLicenseAgreement", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for option and license agreement", "label": "Payments For Option And License Agreement", "documentation": "Payments for option and license agreement." } } }, "auth_ref": [] }, "ka_SmallBusinessAdministrationLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SmallBusinessAdministrationLoanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Small Business Administration Loan", "label": "Small Business Administration Loan [Member]", "documentation": "Small business administration loan." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedTotalLabel": "Accrued expenses and other current liabilities", "negatedTerseLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r88" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ka_RichardPetersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RichardPetersMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Richard Peters", "label": "Richard Peters [Member]", "documentation": "Richard Peters [Member]" } } }, "auth_ref": [] }, "ka_VotingCommonSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "VotingCommonSharesIssued", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, voting rights", "label": "Voting Common Shares Issued", "documentation": "Voting common, shares, issued." } } }, "auth_ref": [] }, "ka_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpiredEndDate": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpiredEndDate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Class Of Warrant Or Right Date From Which Warrants Or Rights Expired End Date", "documentation": "Class of warrant or right date from which warrants or rights expired end date." } } }, "auth_ref": [] }, "ka_RepaymentsOfFinanceLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RepaymentsOfFinanceLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of finance lease liabilities", "label": "Repayments Of Finance Lease Liabilities", "documentation": "Repayments of finance lease liabilities." } } }, "auth_ref": [] }, "ka_AssetAcquisitionsPolictTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "AssetAcquisitionsPolictTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisitions Polict Text Block", "label": "Asset Acquisitions Polict Text Block", "terseLabel": "Asset Acquisitions" } } }, "auth_ref": [] }, "ka_DevelopmentAndRegulatoryMilestonesMaximumAmountExpectedToPay": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DevelopmentAndRegulatoryMilestonesMaximumAmountExpectedToPay", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development and regulatory milestones, aggregate amount payable", "label": "Development And Regulatory Milestones Maximum Amount Expected To Pay", "documentation": "Development and regulatory milestones, maximum amount expected to pay." } } }, "auth_ref": [] }, "ka_GenentechIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "GenentechIncMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genentech,Inc.", "label": "Genentech Inc [Member]", "documentation": "Genentech, Inc." } } }, "auth_ref": [] }, "ka_BalanceSheetComponentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "BalanceSheetComponentsTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Balance Sheet Components [Table]", "label": "Balance Sheet Components [Table]" } } }, "auth_ref": [] }, "ka_DecreaseForProvisionOfResearchsServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DecreaseForProvisionOfResearchsServices", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfCollaborationRevenueAgreementAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Decrease for provision of researchs services", "documentation": "Decrease for provision of researchs services" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r863" ] }, "ka_PrivateKinetasShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PrivateKinetasShareholdersMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Private Kinetas Shareholders [Member]", "label": "Private Kinetas Shareholders [Member]" } } }, "auth_ref": [] }, "ka_OrganizationAndLiquidityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OrganizationAndLiquidityLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization And Liquidity [Line Items]", "label": "Organization And Liquidity [Line Items]", "documentation": "Organization and liquidity." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock vested, description", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Payable", "label": "Convertible Notes Payable [Member]", "verboseLabel": "Convertible notes, if converted", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r110", "r159" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate", "terseLabel": "Excise tax", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r471" ] }, "ka_MergerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MergerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Merger [Member]", "label": "Merger [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r23" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r921", "r926" ] }, "ka_MergerAgreementExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MergerAgreementExchangeRatio", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Merger Agreement Exchange Ratio", "documentation": "Merger agreement exchange ratio.", "terseLabel": "Merger agreement exchange ratio" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective Income Tax Rate Reconciliation, Deduction, Percent, Total", "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "terseLabel": "Corporate minimum tax", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions." } } }, "auth_ref": [ "r921", "r926" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r170", "r626", "r695", "r720", "r825", "r841", "r859" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtRefinancedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtRefinancedAmount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Refinanced, Amount", "terseLabel": "Refinanced notes payable", "documentation": "Amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r59" ] }, "ka_DebtInstrumentOutstandingPrincipalAndAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "DebtInstrumentOutstandingPrincipalAndAccruedInterest", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument,outstanding principal and accrued interest", "label": "Debt Instrument Outstanding Principal And Accrued Interest", "documentation": "Debt instrument,outstanding principal and accrued interest." } } }, "auth_ref": [] }, "ka_VestedRestrictedStockSubjectToRecallMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "VestedRestrictedStockSubjectToRecallMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Vested Restricted Stock Subject To Recall [Member]", "documentation": "Vested restricted stock subject to recall member", "terseLabel": "Vested restricted stock subject to recall [Member]" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r300", "r301", "r302" ] }, "ka_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversionOfNotesPayable", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of 2022 & 2020 notes payable", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion Of Notes Payable", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability conversion of notes payable." } } }, "auth_ref": [] }, "ka_TwoThousandTwentyTwoConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyTwoConvertibleNotesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Convertible Notes", "label": "Two Thousand Twenty Two Convertible Notes [Member]", "documentation": "Two thousand twenty two convertible notes." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of Exercise Price", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r392" ] }, "ka_UnvestedRestrictedStockSubjectToRepurchaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "UnvestedRestrictedStockSubjectToRepurchaseMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Unvested Restricted Stock Subject To Repurchase [Member]", "documentation": "Unvested restricted stock subject to repurchase member", "terseLabel": "Unvested restricted stock subject to repurchase [Member]" } } }, "auth_ref": [] }, "ka_FinancingRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FinancingRangeMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Range", "label": "Financing Range[Member]", "documentation": "Financing Range[Member]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal income taxes", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r225", "r471", "r493" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent", "terseLabel": "Partnership income attributable to non-controlling interest", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes." } } }, "auth_ref": [ "r921", "r926" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on extinguishments of debt, net", "label": "Gain (Loss) on Extinguishment of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "terseLabel": "(Loss) gain on extinguishments of debt, net", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r60", "r61" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ka_IssuanceOfWarrantsToExistingStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfWarrantsToExistingStockholders", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Issuance of warrants to existing stockholders", "label": "Issuance of warrants to existing stockholders", "terseLabel": "Issuance Of Warrants" } } }, "auth_ref": [] }, "ka_IssuanceOfWarrantsToPurchaseCommonStockInConnectionWithNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "IssuanceOfWarrantsToPurchaseCommonStockInConnectionWithNotesPayable", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of warrants to purchase common stock in connection with notes payable", "documentation": "Issuance of warrants to purchase common stock in connection with notes payable.", "label": "Issuance Of Warrants To Purchase Common Stock In Connection With Notes Payable", "terseLabel": "Issuance of warrants to purchase common stock in connection with notes payable" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r24" ] }, "ka_NonrecourseVestedStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NonrecourseVestedStockOptionsExercised", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested stock options exercised", "label": "Nonrecourse Vested Stock Options Exercised", "documentation": "Nonrecourse vested stock options exercised." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r122", "r736" ] }, "ka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restricted Cash", "terseLabel": "Restricted cash" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currencies", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r547" ] }, "ka_RightsFromPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RightsFromPrivatePlacement", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Rights from Private Placement", "label": "Rights from Private Placement", "terseLabel": "Rights from Private Placement" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r22" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r31", "r66", "r140", "r141", "r349" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r158", "r200", "r224", "r264", "r284", "r290", "r303", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r504", "r508", "r541", "r624", "r725", "r825", "r841", "r885", "r886", "r941" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r50" ] }, "ka_VotingCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "VotingCommonStockMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Voting common stock", "label": "Voting Common Stock [Member]", "documentation": "Voting common stock." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ka_LiabilitiesRelatedToSarShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LiabilitiesRelatedToSarShares", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "LIabilities related to SAR Shares", "label": "LIabilities related to SAR Shares", "terseLabel": "Liabilities related to SAR" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "terseLabel": "Research and development tax credits", "verboseLabel": "In-process research and development", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r921", "r926" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r14" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r256" ] }, "ka_TwoThousandTwentyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyWarrantsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020", "label": "Two Thousand Twenty Warrants [Member]", "documentation": "2020 warrants." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other, net", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r921", "r926" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r15" ] }, "ka_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "ka_PaycheckProtectionProgramLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "PaycheckProtectionProgramLoanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paycheck Protection Program", "label": "Paycheck Protection Program Loan [Member]", "documentation": "Paycheck Protection Program Loan." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r568" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r502" ] }, "ka_FairValueOptionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueOptionPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Option", "label": "Fair Value Option Policy [Text Block]", "documentation": "Fair value option." } } }, "auth_ref": [] }, "ka_NumberOfRelatedParties": { "xbrltype": "integerItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "NumberOfRelatedParties", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of related parties", "label": "Number Of Related Parties", "documentation": "Number of related parties." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r120" ] }, "ka_OptionAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OptionAndLicenseAgreementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option and License Agreement", "label": "Option And License Agreement [Member]", "documentation": "Option and license agreement." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeDisclosureAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeasesSupplementalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]", "verboseLabel": "Finance Leases:", "terseLabel": "Operating Lease:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory note payment, Description", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r74", "r76" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidity" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Liquidity", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r109", "r153", "r669", "r670" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares granted, shares", "terseLabel": "Shares available for future grants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Stock Options, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Outstanding Stock Options, Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r431" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Stock Options, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Outstanding Stock Options, Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Stock Options, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "verboseLabel": "Options granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r899" ] }, "us-gaap_InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense on Prepetition Liabilities Recognized in Statement of Operations", "terseLabel": "Non cash interest expense on the statement of operations", "documentation": "The amount of interest expense on prepetition obligations included in the statement of operations." } } }, "auth_ref": [ "r940" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding Stock Options as of March 31, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "Options outstanding", "periodStartLabel": "Outstanding as of June 30, 2023", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r424", "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted- Average Exercise Price Per Share, Beginning Balance", "periodEndLabel": "Weighted- Average Exercise Price Per Share, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r424", "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r426" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "terseLabel": "Net loss attributable to Kineta, Inc.", "label": "Net Income (Loss)", "totalLabel": "Net income (loss) attributable to Kineta, Inc.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r119", "r129", "r163", "r194", "r206", "r207", "r211", "r224", "r233", "r237", "r238", "r239", "r240", "r243", "r244", "r252", "r264", "r283", "r289", "r291", "r303", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r533", "r541", "r636", "r733", "r755", "r756", "r802", "r839", "r885" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted- Average Exercise Price Per Share, Exercisable as of June 30, 2023", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r441" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "terseLabel": "Expected dividend", "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends." } } }, "auth_ref": [ "r446" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r446" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r445" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Options [Member]", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r447" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable as of June 30, 2023", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r441" ] }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfNotesPayable", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Conversions of notes payable", "label": "Proceeds from (Repayments of) Notes Payable", "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r417", "r418", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfFairValueOfStockOptionsGrantedForEmployeeAndNonEmployeeAwardsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r417", "r418", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Outstanding Stock Options, Exercisable as of June 30, 2023", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r441" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities, net of current portion", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r564" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r194", "r206", "r207", "r216", "r224", "r233", "r243", "r244", "r264", "r283", "r289", "r291", "r303", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r503", "r506", "r507", "r533", "r541", "r622", "r634", "r683", "r733", "r755", "r756", "r802", "r822", "r823", "r840", "r864", "r885" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Liability, Total", "label": "Finance Lease, Liability", "terseLabel": "Financing lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r564", "r574" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r247", "r256", "r257", "r258" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "label": "Equity, Attributable to Noncontrolling Interest", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r37", "r161", "r224", "r303", "r337", "r339", "r340", "r341", "r344", "r345", "r541", "r629", "r714" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities, current portion", "label": "Finance Lease, Liability, Current", "negatedTerseLabel": "Less: Financing lease liabilities, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r564" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r187", "r202", "r203", "r204", "r224", "r250", "r251", "r253", "r255", "r261", "r262", "r303", "r337", "r339", "r340", "r341", "r344", "r345", "r377", "r378", "r381", "r384", "r391", "r541", "r673", "r674", "r675", "r676", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r696", "r712", "r734", "r757", "r782", "r783", "r784", "r785", "r786", "r853", "r868", "r876" ] }, "us-gaap_AccountingStandardsUpdate202104Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate202104Member", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update 2021-04", "label": "Accounting Standards Update 2021-04 [Member]", "documentation": "Accounting Standards Update 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)." } } }, "auth_ref": [ "r534" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFinanceLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r574" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Paid-in-Kind Interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtGainLossNetOfTax", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Extinguishment of Debt, Gain (Loss), Net of Tax", "negatedLabel": "Gain on extinguishments of debt, net", "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax." } } }, "auth_ref": [ "r60" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r93", "r155", "r206", "r207", "r243", "r244", "r635", "r864" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfExpectedFutureMinimumPrincipalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Current", "totalLabel": "Notes Payable, Current, Total", "verboseLabel": "Less: current portion", "terseLabel": "Notes payable, current portion", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r25" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r135", "r331", "r332", "r789", "r882" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliated with Board of Directors", "label": "Affiliated Entity [Member]" } } }, "auth_ref": [ "r732", "r790", "r831", "r891", "r936", "r937", "r939" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r85", "r86", "r497" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable", "totalLabel": "Notes payable, net of current portion", "label": "Notes Payable, Noncurrent", "verboseLabel": "Notes payable, net of current portion", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle accounting standards update, immaterial effect", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": [ "r180", "r233", "r245", "r309", "r488" ] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investments and Cash", "totalLabel": "Investments and Cash, Total", "terseLabel": "Unrestricted cash", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r951", "r953" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r563" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r918" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Total Stock-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r80" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareParentheticalDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price", "label": "Share Price", "verboseLabel": "Conversion Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "srt_ManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ManagementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Management [Member]", "terseLabel": "Senior Management Team" } } }, "auth_ref": [ "r879", "r938" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r865" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r878" ] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r843" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r132" ] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors", "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from notes payable", "label": "Proceeds from Notes Payable", "totalLabel": "Proceeds from Notes Payable, Total", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares issued", "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r113" ] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefFinancialOfficerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Financial Officer", "label": "Chief Financial Officer [Member]" } } }, "auth_ref": [ "r879" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Member of Board of Directors", "label": "Director [Member]" } } }, "auth_ref": [ "r879", "r956" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r852" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable", "totalLabel": "Notes payable, net of current portion", "terseLabel": "Total notes payable", "verboseLabel": "Notes payable, net of current portion", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r20", "r160", "r952" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseFutureUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Lease [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 125,000 shares authorized as of September 30, 2023 and December 31, 2022; 10,215 and 8,318 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively", "verboseLabel": "Aggregate fair market value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r113", "r627", "r825" ] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ExecutiveOfficerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationDetail", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Expense recognized", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r449", "r461" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerSummaryOfPurchasePricePaidInMergerDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Share Price", "terseLabel": "Multiplied by fair value per share of Yumanity common stock", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r113", "r712" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r113", "r712", "r731", "r959", "r960" ] }, "us-gaap_NonvotingCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvotingCommonStockMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-voting Common Stock", "label": "Nonvoting Common Stock [Member]", "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "terseLabel": "License revenue recognized", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r265", "r266", "r282", "r287", "r288", "r292", "r293", "r294", "r402", "r403", "r605" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of 2022 convertible notes", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r97" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Partial settelement of 2020 notes payable", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r97" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for stock options and restricted stock units to purchase common stock under equity incentive plans", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Description of Transaction", "terseLabel": "Sell and purchase of its common stock, description", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination." } } }, "auth_ref": [ "r12", "r91", "r154" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r843" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r108", "r463", "r949" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLimitationsOnUse", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards, Limitations on Use", "terseLabel": "Operating loss carryforwards, limitations on use", "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Revenue Agreement", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r186", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r404" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r226", "r227", "r350", "r379", "r586", "r796", "r798" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r57" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "terseLabel": "Liabilities, current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r29", "r196", "r224", "r303", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r505", "r508", "r509", "r541", "r825", "r885", "r941", "r942" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r83" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Revenues", "totalLabel": "Revenues, Total", "verboseLabel": "Commercial revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r213", "r224", "r265", "r266", "r282", "r287", "r288", "r292", "r293", "r294", "r303", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r541", "r622", "r885" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r264", "r283", "r289", "r291", "r802" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Grant revenues [Member]", "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r890" ] }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLossAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "ka_RepaymentRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RepaymentRangeMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment Range", "label": "Repayment Range[Member]", "documentation": "Repayment Range[Member]" } } }, "auth_ref": [] }, "ka_MilestonesAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MilestonesAchieved", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestones achieved", "label": "Milestones Achieved", "documentation": "Milestones achieved." } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromBankDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromBankDebt", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan proceeds", "label": "Proceeds from Bank Debt", "documentation": "The cash inflow from bank borrowing during the year." } } }, "auth_ref": [ "r39" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment", "terseLabel": "Purchases of property and equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r126" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r412", "r584", "r585", "r705", "r706", "r707", "r708", "r709", "r730", "r732", "r764" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r845" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Allocation of Purchase Price to Net Tangible and Intangible Assets", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r151" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompaniesRestrictedStockActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r437" ] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock for Future Issuance", "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": [ "r21", "r62", "r64", "r65", "r66", "r67", "r68", "r69", "r112", "r113", "r139", "r141", "r142" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r107", "r174" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r63", "r64", "r65", "r66", "r67", "r68", "r69", "r139", "r141", "r142", "r202", "r203", "r204", "r261", "r377", "r378", "r379", "r381", "r384", "r389", "r391", "r673", "r674", "r675", "r676", "r811", "r853", "r868" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r202", "r203", "r204", "r261", "r377", "r378", "r379", "r381", "r384", "r389", "r391", "r673", "r674", "r675", "r676", "r811", "r853", "r868" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r820", "r922" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r30", "r100", "r365" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, effective percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r30", "r100", "r375", "r558" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r103", "r104", "r737", "r738", "r741" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r30", "r348" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share sold", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r581", "r582", "r583", "r585", "r587", "r679", "r680", "r681", "r739", "r740", "r741", "r761", "r763" ] }, "us-gaap_DebtInstrumentInterestRateTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateTerms", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate terms", "label": "Debt Instrument, Interest Rate Terms", "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets." } } }, "auth_ref": [ "r30" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r224", "r303", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r505", "r508", "r509", "r541", "r710", "r801", "r841", "r885", "r941", "r942" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r185", "r806", "r932" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r737", "r738", "r741" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromRentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRentsReceived", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Rents Received", "terseLabel": "Proceeds from rent", "documentation": "Cash received for rents during the current period." } } }, "auth_ref": [ "r42" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Aggregate purchase price", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r673" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableScheduleOfNotesPayableDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r32", "r228", "r347", "r348", "r349", "r350", "r351", "r353", "r358", "r359", "r360", "r361", "r363", "r364", "r365", "r366", "r367", "r368", "r558", "r806", "r807", "r808", "r809", "r810", "r869" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r118", "r162", "r630", "r825", "r870", "r880", "r933" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r33", "r105", "r625", "r711" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from Issuance of Private Placement", "verboseLabel": "Proceeds from private placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r588", "r590" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r847" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred Revenue, Current", "totalLabel": "Deferred Revenue, Current, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r861" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r932" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle accounting standards update, adopted", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r181", "r182", "r183", "r188", "r189", "r232", "r298", "r299", "r304", "r305", "r306", "r312", "r313", "r327", "r484", "r499", "r500", "r510", "r511", "r512", "r523", "r524", "r534", "r539", "r540", "r542", "r543", "r544", "r555", "r559", "r560", "r561", "r576", "r606", "r607", "r657", "r658" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r169", "r184", "r243", "r244", "r272", "r470", "r490", "r638" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Rent", "terseLabel": "Payments for rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r3" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating losses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r84", "r925" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r329", "r330", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r805", "r857", "r954" ] }, "ka_ThierryGuillaudeuxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ThierryGuillaudeuxMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thierry Guillaudeux", "label": "Thierry Guillaudeux [Member]", "documentation": "Thierry Guillaudeux [Member]" } } }, "auth_ref": [] }, "ka_CashPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CashPaymentsReceived", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStrategicLicenseAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "cash payments Received", "label": "cash payments Received", "terseLabel": "Cash payments Received" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets less valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r924" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle accounting standards update, adoption date", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r181", "r182", "r183", "r188", "r189", "r298", "r299", "r304", "r305", "r306", "r312", "r313", "r314", "r327", "r484", "r499", "r500", "r501", "r510", "r511", "r512", "r513", "r523", "r524", "r525", "r528", "r534", "r539", "r540", "r542", "r543", "r544", "r555", "r559", "r560", "r561", "r576", "r606", "r607", "r657", "r658", "r856" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to related party", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r41" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Change in valuation allowance", "verboseLabel": "Less: Valuation allowance", "negatedLabel": "Less: Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r480" ] }, "ka_RepaymentScenarioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "RepaymentScenarioMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment Scenario", "label": "Repayment Scenario [Member]", "documentation": "Repayment scenario." } } }, "auth_ref": [] }, "ka_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInNotesPayable", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of 2022 & 2020 notes payable", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Notes Payable", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability change in notes payable." } } }, "auth_ref": [] }, "ka_ImmediatelyFollowingMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ImmediatelyFollowingMergerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureReverseMergerAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Immediately following merger member", "label": "Immediately Following Merger [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Net deferred tax assets", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r84", "r925" ] }, "ka_OperatingLossCarryforwardLimitPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "OperatingLossCarryforwardLimitPercentage", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforward limit percentage", "label": "Operating Loss Carryforward Limit Percentage", "terseLabel": "Operating loss carryforward limit, percentage" } } }, "auth_ref": [] }, "ka_TransactionCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TransactionCosts", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "documentation": "Transaction costs", "label": "Transaction costs" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r412", "r584", "r585", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r705", "r706", "r707", "r708", "r709", "r730", "r732", "r764", "r939" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r413" ] }, "ka_TwoThousandTwentyNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandTwentyNotesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Notes [Member]", "documentation": "Two thousand twenty notes.", "terseLabel": "2020 Notes" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r137", "r347", "r348", "r358", "r359", "r360", "r364", "r365", "r366", "r367", "r368", "r806", "r807", "r808", "r809", "r810" ] }, "ka_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod": { "xbrltype": "sharesItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfCompaniesRestrictedStockActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Stock, Released", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod", "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Pronouncements Recently Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r217" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ka_ScheduleOfOperatingLeasesSupplementalInformation": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ScheduleOfOperatingLeasesSupplementalInformation", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Operating Leases Supplemental Information [Table Text Block]", "terseLabel": "Schedule of Operating Leases Supplemental Information", "documentation": "Schedule of Operating Leases Supplemental Informatio [Table Text Block]" } } }, "auth_ref": [] }, "ka_MerckNeuromuscularLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MerckNeuromuscularLicenseAgreementMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Merck Neuromuscular License Agreement Member", "label": "Merck Neuromuscular License Agreement [Member]", "terseLabel": "Merck Neuromuscular License Agreement" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development credits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r83", "r84", "r925" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNotesPayableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debt", "label": "Convertible Debt", "totalLabel": "Convertible Debt, Total", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r20", "r160", "r952" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r217" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r82" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r846", "r848", "r849" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r793" ] }, "ka_TwoThousandNineteenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandNineteenWarrantsMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfWarrantsToPurchaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019", "label": "Two Thousand Nineteen Warrants [Member]", "documentation": "2019 warrants." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r127", "r128", "r129" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net", "totalLabel": "Total deferred tax liabilities", "negatedTotalLabel": "Total deferred tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r81", "r924" ] }, "ka_BalanceSheetComponentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "BalanceSheetComponentsAbstract", "lang": { "en-us": { "role": { "documentation": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ka_CommonStockPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "CommonStockPurchasePrice", "crdr": "debit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock purchase price", "label": "Common stock purchase price", "terseLabel": "Common stock purchase price" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Leasing Arrangements", "terseLabel": "Right-of-use asset", "negatedLabel": "Right-of-use asset", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r84", "r925" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInTheFairValueOfTheRightsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r360", "r406", "r407", "r408", "r409", "r410", "r411", "r536", "r593", "r807", "r808", "r813", "r814", "r815" ] }, "ka_WainwrightCoLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "WainwrightCoLlcMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wainwright & Co., LLC", "label": "Wainwright & Co., LLC [Member]", "documentation": "Wainwright & Co., LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementSummaryOfCollaborationRevenueAgreementAndDeferredRevenueDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureLicensingRevenueAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance as of end of period", "periodStartLabel": "Balance as of beginning of period", "totalLabel": "Deferred Revenue, Total", "label": "Deferred Revenue", "terseLabel": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r862" ] }, "ka_SummaryOfCollaborationRevenueAgreementAndDeferredRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "SummaryOfCollaborationRevenueAgreementAndDeferredRevenueTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureCollaborationAgreementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of collaboration revenue agreement and deferred revenue", "label": "Summary of collaboration revenue agreement and deferred revenue Table Text Block", "documentation": "Summary of collaboration revenue agreement and deferred revenue Table Text Block" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Net Loss per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r877" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock-based compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r84", "r925" ] }, "ka_LicenseAgreementsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "LicenseAgreementsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "License Agreements Disclosure [Abstract]", "documentation": "License agreements disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r843" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other asset", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r199" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r215", "r218", "r219" ] }, "ka_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInDebtExtinguishment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInDebtExtinguishment", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOf20222020NotesPayableMeasuredUsingLevel3InputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of debt extinguishment", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Debt Extinguishment", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability change in debt extinguishment." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOtherFiniteLivedAssets", "crdr": "credit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Other Finite-Lived Assets", "terseLabel": "Fixed assets", "negatedLabel": "Fixed assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment." } } }, "auth_ref": [ "r84", "r925" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r84", "r925" ] }, "ka_ChiefScientificOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ChiefScientificOfficerMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Scientific Officer", "label": "Chief Scientific Officer [Member]", "documentation": "Chief Scientific Officer [Member]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfPrivatePlacement", "crdr": "credit", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureOrganizationAndLiquidityAdditionalInformationDetails", "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Payments for private placement", "label": "Payments for Repurchase of Private Placement", "terseLabel": "Rights from Private Placement", "documentation": "The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r40" ] }, "ka_MaturityDatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "MaturityDatesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity Dates", "label": "Maturity Dates[Member]", "documentation": "Maturity Dates[Member]" } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/DisclosureShareholdersEquityScheduleOfCommonStockForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r697", "r698", "r699", "r700", "r701", "r765", "r767", "r769", "r772", "r773", "r774", "r775", "r777", "r778", "r779", "r780", "r781", "r830" ] }, "ka_ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "ConvertibleNotesMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes [Member]", "label": "Convertible Notes [Member]", "documentation": "Convertible notes member" } } }, "auth_ref": [] }, "ka_TwoThousandAndEightEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kinetabio.com/20230930", "localname": "TwoThousandAndEightEquityIncentivePlanMember", "presentation": [ "http://www.kinetabio.com/20230930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Eight Equity Incentive Plan [Member]", "label": "Two Thousand And Eight Equity Incentive Plan [Member]", "terseLabel": "2008 Equity Incentive Plan [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20,22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//985-730/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481260/860-50-45-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481260/860-50-45-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481260/860-50-45-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r853": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r854": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r855": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-11" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" } } }